Tonix Has Successor Drugs In Early Development As Analysts Press On TONMYA Patent Protection

Management says core patents protect TONMYA into 2034 and describes successor research as small beside its depression trial.

Share
Tonix Has Successor Drugs In Early Development As Analysts Press On TONMYA Patent Protection

Tonix Pharmaceuticals, which sells and develops drug therapies, has begun early work on successor treatments targeting non-restorative sleep while facing a generic challenge to its fibromyalgia drug TONMYA. Chief Executive Officer Seth Lederman told analysts on Monday’s earnings call that the company’s core patents, as currently granted, provide protection into 2034.

Early Research, A Longer Patent Horizon

An analyst asked about both litigation milestones and next-generation products that might extend patent life. Lederman opened with a caution: "Unfortunately, two questions for which I can't give you a lot of clarity."

On successor products, however, he confirmed that "we do have some very early work underway." Tonix hopes to introduce, test and secure approval for next-generation treatments aimed at non-restorative sleep. Lederman connected that research to the company’s work on sleep and widespread pain in fibromyalgia and other overlapping chronic pain conditions, including chronic fatigue syndrome and post-treatment Lyme disease syndrome.

The early research is a small expense compared with Tonix’s clinical study in major depressive disorder, Lederman said: "it doesn't cost enough to be something that we would materially comment on" relative to that trial. Tonix is enrolling adults in the six-week depression study, which could expand TONMYA’s approved uses.

Dr. Reddy’s Challenges The Patents

Tonix disclosed on October 2, 2026, that Dr. Reddy’s had filed a generic application containing a certification challenging TONMYA’s patents. The company said it intended to enforce its rights but could not predict the outcome.

Responding to a TD Cowen analyst on the call, Lederman said the patents cover formulation technology and other distinctive product characteristics. He pledged to defend that intellectual property vigorously.

Lederman said the response process follows the Hatch-Waxman Act, citing a 45-day response period and a 30-month stay. Those legal mechanics and the early successor research were separate parts of management’s answer; the next-generation products remain development work, not approved replacements.

A Growing Launch, With Higher Spending

TONMYA, an FDA-approved tablet taken under the tongue for adults with fibromyalgia, launched on November 17, 2025. Tonix also sells the acute migraine treatments Zembrace SymTouch and Tosymra.

TONMYA generated approximately $15 million in third-quarter net sales, up 37% from the second quarter. Chief Commercial Officer Thomas Englese said prescriptions rose 28% to 16,375, with new prescriptions up 17% and refills up 56% from the second quarter. Insurance coverage now reaches approximately 53% of covered U.S. lives, and Tonix expanded its sales force to 150 representatives on September 1.

Chief Financial Officer Bradley Saenger reported approximately $17.2 million in total third-quarter product revenue, compared with $3.3 million a year earlier, before TONMYA’s launch. Selling, general and administrative spending rose to approximately $45.6 million from $25.7 million, primarily because of launch-related sales, marketing, employee and professional expenses.

Tonix ended September with approximately $162.8 million in cash and cash equivalents, versus $207.6 million at the end of 2025. Management expects that cash, together with proceeds from equity offerings after quarter-end, to fund operations and capital spending into the early third quarter of 2027.

TNXP shares plunged about 9% to $4.30 in Monday trading. The decline was not established as a response to any particular management remark.

For now, Tonix is pursuing the depression trial as a possible expansion of TONMYA’s uses while keeping successor research at a very early stage.

Sources

More on Tonix Pharmaceuticals

All Tonix Pharmaceuticals (TNXP) coverage →